Academic Journal of Medical Sciences
ISSN: 2708-2725
REVIEW ARTICLE

Community-Acquired Pneumonia: Literature Review

Talin P. Avag, Hagop I. Aleksandr

D.M., Pulmonology, Apollo Hospitals, Pulmonology Department, Kolkata

Pneumonia is one of the most concerning diseases worldwide, with the lungs' air sac inflating due to an infection by bacterial, viral and rarely, fungal or protozoan entities. The disease presents itself with a combination of coughs, chest discomfort, fever, and breathing difficulties, while treatment and detection need the aid of sputum cultures and chest X rays. Vaccines are available for some of the known pathogens causing pneumonia, however, general antibiotics significantly boosts recovery rates. But despite how effective those treatment methods are, pneumonia remains a considerable risk to developing countries, elderly people, and those suffering from chronic illnesses.

Prevalence and Impact

The occurrence of pneumonia on a global scale is estimated to be around 450 million per year, with deaths reaching 4 million. Progress in technology and medicine does not seem to dampen the devastating impact pneumonia has, especially on children and the elderly. It seems to be especially more pronounced in developing countries where viral pneumonia accounts for an astounding number of cases.

Etiology and Risk Factors

The main causes of pneumonia are bacteria and viruses with bacterial pneumonia being the most wide-spread type of pneumonia in the community. Streptococcus pneumoniae is the primary bacterial infection noticed in nearly one half of the patients, then comes Haemophilus influenzae and Mycoplasma pneumoniae. Risk factors for pneumonia include smoking, immunodeficiency, alcoholism, chronic lung diseases, and advanced age. Use of acid suppressing medications may also be a risk factor.

Bacterial Causes

Bacterial infection is the primary cause of community acquired pneumonia as many different types of bacteria with high antibiotic resistance develop community-acquired pneumonia. Numerous studies have shown that alcoholism and smoking tend to have a considerably elevated risk ratio for pneumonial sine. Many other types of pneumonia are caused with a mixture of these two factors which makes things even more difficult.

Viral Causes

Viruses are responsible for approximately a third of adult pneumonia cases, and an even smaller percentage in children. In some cases of viral pneumonia, secondary bacterial infections can emerge, and this is especially true for patients with other underlying comorbidities.

Fungal and Protozoan Pneumonia

Fungal pneumonia is infrequent, yet it is significantly more common in patients suffering from other lung diseases. The typical fungus are Histoplasma and Pneumocystis jirovecii. Infection of the lungs by protozoa is rare and takes place primarily in cases of a weakened immune response.

Clinical Presentation and Diagnosis

Diagnosis of both pneumonia and Community-Acquired Pneumonia (CAP) is done via clinical manifestation and advanced lung imaging s. While fellow clinicians consider fever, cough accompanied with sputum, and other physical findings as symptoms, with no X-Ray or CT scan, the diagnosis can solely be administered based on clinical evaluation and in thorough assessment of patient history.

In relation to the blockages that pneumonia can cause, patients are compartmentalized in four groups based on severity and other comorbidities:

Group I: Patients within the milder section who would not require hospitalization due to mild infection, common pathogens like S. pneumoniae.

Group II: Patients with stress and infection comorbidities, like fistula inflammation, can contain other more concerning antibiotic-resistant strains.

Group III: A significant proportion of patients can be grouped here as these are the patients requiring hospitalization and showing a range of symptoms, frequently older experiencing a mix of pathogens.

Group IV: Patients within this stratum will need severe caring attention and encompass putative pathogens, as some will need intensive support.

Prognosis and Complications

As consideration for exudative pleurisy, lung abscess, and respiratory failure, clinical exercises and specially above-mentioned checks the Pneumonia Severity Index and CURB-65 scale help formulate a more accurate guess on the outcomes and plan the required treatment. Having said that, fellow physicians will routinely draw the line at severe pneumonia which can evolve towards acute respiratory distress syndrome or ARDS and sepsis, especially for someone with a compromised immune system.

Prevention Strategies

These measures include the immunization against the damaging microorganisms, increasing the accessibility of health care services, and targeting other important health determinants. The influenza virus as well as bacterial pneumonia and Haemophilus influenzae vaccines manufactured have proven their efficacy. Other strategies of prevention involve alteration of some behaviors like cessation of smoking and enhancement of the environmental air quality, both of which can lower the chance of developing pneumonia.

In children, exclusively breastfeeding and appropriate immunizations can bring the rates of pneumonia down. In other susceptible populations such as the elderly, adequate care of the mouth cavity together with screening and treatment of infection during pregnancy can mitigate some risks.

In summary, pneumonia is still a major public health issue that continues to necessitate integrated efforts to control the disease and its complications especially for vulnerable groups. Advanced studies on identifying risk factors and overcoming them, while increasing coverage of vaccination, as well as ensuring that prompt medical care is provided stand to be the most important ways of controlling and preventing this disease.

1. (CDC) C for DC and P. Achievements in public health, 1900–1999: control of infectious diseases. MMWR Morb Mortal Wkly Rep. 1999;48:621–9.
2. A. D. The quality of care: how can it be assessed? JAMA. 1988;260:1743–8.
3. Lohr KL editor. Medicare: a strategy for quality assurance, volume I. Washington, DC: The National Academies Press; 1990.
4. AH. L. The changing spectrum of fungal infections in pulmonary and critical care practice: clinical approach to diagnosis. Proc Am Thorac Soc. 2010;7:163–8.
5. AH. L, KS. K, GA. S, NM. A, JE. B, A. C, et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183:96–128.
6. DS. M, JP. M. Pulmonary histoplasmosis. Semin Respir Crit Care Med. 2011;32:735–44.
7. III. TGR. Pulmonary coccidioidomycosis. Semin Respir Crit Care Med. 2011;32:754–63.
8. HY. S, N. S. Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis. 2011;11:301–11.
9. G. H, G. S, DP. K. Pulmonary mucormycosis. Semin Respir Crit Care Med. 2011;32:693–702.
10. M. K, R. T, AO. S. Pulmonary aspergillosis: a clinical review. Eur Respir Rev. 2011;20:156–74.

11. B. B, KF. R, LM. F. Phosphodiesterase-4 inhibitor therapy for lung diseases. Am J Respir Crit Care Med. 2013;188:271–8.
12. CP. P, D. S. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol. 2012;12:275–86.
13. S. J, WH. S, RG. W, al. et. Community-Acquired Pneumonia requiring hospitalization among U.S. adults. N Engl J Med Overseas Ed. 2015;373:415–27.
14. C. G. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743–800.
15. Organisation WH. The top 10 causes of death [Internet]. 2017. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/
16. AF. S, MD. Z, ST. M, al. et. Viruses are prevalent in non-ventilated hospital-acquired pneumonia. Respir Med. 2017;122:76–80.
17. HL. H, SB. H, GB. K, al. et. Viral infection is not uncommon in adult patients with severe hospital-acquired pneumonia. PLoS One. 2014;9(e95865).
18. CA. L, al. et. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294:2043–51.
19. Y. A, WS. L, L. L, al. et. Systematic review of respiratory viral pathogens identified in adults with community-acquired pneumonia in Europe. J Clin Virol. 2017;95:26–35.
20. O. R, E. L, LC. J, al. et. Viral pneumonia. Lancet. 2011;377:1264–75.
21. D. ÇS, H. P, C. Ç, al. et. Bacterial and viral etiology in hospitalized community acquired pneumonia with molecular methods and clinical evaluation. J Infect Dev Ctries. 2014;8:510–8.
22. T. H, E. N, S. K, al. et. The utility of biomarkers in differentiating bacterial from non-bacterial lower respiratory tract infection in hospitalized children: difference of the diagnostic performance between acute pneumonia and bronchitis. J Infect Chemother. 2014;20:616–20.
23. O. D, P. R, S. de las H, al. et. Clinical presentation and characteristics of pharyngeal adenovirus infections. Pediatr Infect Dis J. 2005;24:733–4.
24. H. N, E. V, M. L, al. et. Erythrocyte sedimentation rate, white blood cell count and serum C-reactive protein in assessing etiologic diagnosis of acute lower respiratory infections in children. Pediatr Infect Dis J. 1995;14:484–9.

25. K. O, A. C, O. B, al. et. A novel host-proteome signature for distinguishing between acute bacterial and viral infections. PLoS One. 2015;10(e0120012).
26. CB. van H, JAH. de G, A. K, al. et. A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): a double-blind, multicentre, validation study. Lancet Infect Dis. 2017;17:431–40.
27. C. R, AP. C. Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients. Curr Opin Infect Dis. 2011;24:333–43.
28. J-M. BL, H. L, C. K, al. et. Evaluation of commercial ResPlex II v2.0, MultiCode®-PLx, and xTAG® respiratory viral panels for the diagnosis of respiratory viral infections in adults. J Clin Virol. 2011;50:42–5.
29. LA. M, RG. W, A. A, al. et. Infectious diseases society of america/american thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27–72.
30. CDC. Seasonal Influenza (Flu) [Internet]. 2016. Available from: https://www.cdc.gov/flu/professionals/
31. CD. R, A. K. Influenza and endemic viral pneumonia. Crit Care Clin. 2013;29:1069–86.
32. B. H, N. L, M. B, al. et. Influenza virus infections in patients with malignancies characteristics and outcome of the season 2014/15. Eur J Clin Microbiol Infect Dis. 2017;36:565–73.
33. RF. C, S. G, GP. B, al. et. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore). 2006;85:278–87.
34. S. K, H. K, M. M, al. et. Intravenous peramivir for treatment of influenza a and b virus infection in high-risk patients. Antimicrob Agents Chemother. 2011;55:2803–12.
35. R. M, MA. RW, V. L, al. et. Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. Antivir Ther. 2007;12:571–6.
36. N. K, H. I, N. I, al. et. Comparison of the effectiveness of Zanamivir and Oseltamivir against Influenza A/H1N1, A/H3N2, and B. Clin Infect Dis. 2009;48:996–7.
37. Y. H, Y. W, F. L, al. et. Design and expeditious synthesis of organosilanes as potent antivirals

targeting multidrug-resistant influenza A viruses. Eur J Med Chem. 2017;135:70–6.

38. Y. H, J. Z, RG. M, al. et. Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses. Antivir Res. 2017;145:103–13.
39. LA. G, LZ. S, KR. B, al. et. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices — United States, 2017–18 Influenza Season. MMWR Recomm Reports. 2017;66:1–20.
40. JH. B, J. F, AM. H, al. et. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005;353:1374–85.
41. E. B, T. C, Z. G, al. et. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362:1708–19.
42. W. P, M. H, H. H, al. et. Clinical aspects of 2009 pandemic influenza A (H1N1) virus infection in Austria. Infection. 2011;39:341–52.
43. J. T, D. W. Research progress in human infection with avian influenza H7N9 virus. Sci China Life Sci. 2017;
44. RA. M. 1918 influenza virus: 100 years on, are we prepared against the next influenza pandemic? Nat Rev Microbiol. 2018;16:61–2.
45. AR. B, AR. F. Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging. 2015;32:261–9.
46. TC. C. Viruses associated with pneumonia in adults. Clin Infect Dis. 2012;55:107–13.
47. S. A, JE. R, S. S, al. et. Respiratory viruses in transplant recipients: more than just a cold. Clinical syndromes and infection prevention principles. Int J Infect Dis. 2017;62:86–93.
48. Y-J. K, M. B, J. E. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med. 2007;28:222–42.
49. M. B, J. E, Y. L, al. et. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2007;44:245–9.
50. A. W, AP. C, H. X, al. et. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical

outcomes. Clin Infect Dis. 2013;57:1731–41.

51. JR. M, JW. W, RR. R, al. et. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis. 2014;16:242–50.
52. CM. G, E. T, A. T, al. et. Effective use of oral ribavirin for respiratory syncytial viral infections in allogeneic haematopoietic stem cell transplant recipients. J Hosp Infect. 2017;95:214–7.
53. FS. B, LM. C, M. B, al. et. Oral ribavirin for respiratory syncytial virus infection after lung transplantation: Efficacy and cost-efficiency. J Hear Lung Transpl. 2015;34:958–62.
54. A. P, GM. L, SD. F, al. et. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Hear Lung Transpl. 2009;28:67–71.
55. DM. L, RA. B, D. M, al. et. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Antimicrob Agents Chemother. 1996;40:2555–7.
56. AR. G, AIR. S, JM. M, al. et. Intravenous Ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Hear Lung Transpl. 2005;24:2114–9.
57. JN. S, RF. C. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood. 2011;117:2755–63.
58. V. L, GS. D, D. W. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients JO.